RXC-004 is under clinical development by Redx Pharma and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RXC-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RXC-004 overview

RXC-004 is under development for the treatment of pancreatic ductal adenocarcinoma, metastatic biliary tract cancer, intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, metastatic colorectal cancer, pancreatic cancer, gastric cancer and biliary tumor. It is administered orally. The drug candidate targets protein cysteine N palmitoyltransferase porcupine of the Wnt pathway. The drug candidate is developed based on Redox Switch technology. It was under development for the treatment of melanoma.

Redx Pharma overview

Redx Pharma, formerly Redx Pharma is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s major pipeline products include RXC004, RXC007, RXC008, DDR, RXC006/AZD5055, JZP815, among other drug candidates. Its drug products are used for the treatment of pancreatic cancer, idiopathic pulmonary fibrosis (IPF), fibro stenotic crohn’s disease, oncology and fibrosis, and Fibrosis, Cancer-associated fibrosis. Redx Pharma’s redox switch is also used for delivering multiple development candidates over mechanistic approaches in the treatment of cancer. The company conducts research through its facilities in the UK. Redx Pharma is headquartered in Macclesfield, the UK.

For a complete picture of RXC-004’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.